Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
PPMX-T003
DRUG
2 trials
Sponsors
Perseus Proteomics Inc.
, Hiroshima University Hospital
Conditions
Aggressive NK Cell Leukemia
Polycythemia Vera
Phase 1
Safety Evaluation Study for Patients With Polycythemia Vera
NCT05074550
Perseus Proteomics Inc.
Polycythemia Vera
Start: 2022-08-24
End: 2024-03-31
Target: 6
Updated: 2023-07-24
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Recruiting
NCT05863234
Hiroshima University Hospital
Aggressive NK Cell Leukemia
Start: 2023-09-21
End: 2026-03-31
Target: 7
Updated: 2025-04-30
Related Papers
Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia
BMJ Open
2025-06-01
Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia
Blood
2024-11-05
Interim Phase I Safety Study of Anti-Transferrin Receptor Antibody(PPMX-T003) in Patients with Polycythemia Vera
Blood
2023-11-02
1 citations
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
Blood Advances
2023-08-08
8 citations